Lonza plots 2 manufacturing suites for antibody-drug conjugates at Switzerland site

The search for next-gen oncology therapies has sparked an arms race in biopharma to find the next big thing—whether that's in cell and gene therapies or promising antibody-drug conjugates (ADCs). Eyeing that bustling market, Swiss manufacturing giant Lonza is diving even further into ADCs with a new customer on board.